WORLD TRADE ORGANIZATION

TRADE AND PUBLIC HEALTH WORKSHOP

Geneva, 8-12 October 2018

Venue: Room E, Centre William Rappard

The Workshop will review the system of multilateral trade agreements as part of the wider action to address needs specific to public health, and will set this system in the context of the broader factors that impact on innovation and access in the pharmaceutical and medical technology sector. The programme will cover: public health determinants; the IP system; pricing and procurement policies; competition policy and rules; tariffs, quotas and licensing; health services; and regulatory issues, including approval, quality control and effectiveness of medicines, the protection of clinical trial data under the TRIPS Agreement, and health-related measures in the TBT and SPS Committees.

This material will be complemented by a series of discussions dedicated to specific, cross-cutting themes linking trade agreements to topical issues, such as non-communicable diseases and human rights. Exercises and case studies will set these issues in a practical context, requiring participants to examine key thematic issues that involve the consideration of industry policy issues, including as regards local production of medicines and technology transfer, the use of IP flexibilities in order to procure medicines, the application of competition policy tools and their impact on public health objectives, and the dealing with specific trade concerns regarding TBT/SPS measures.

Special attention will be given to the topic "Effectively Using Special Compulsory Licences for Export as a Procurement Tool for Medicines". Since the entry into force of the Protocol Amending the TRIPS Agreement, in January 2017, this public health flexibility is an integral part of the TRIPS Agreement. The Workshop will look at how best to effectively use this tool, as well as the practical options for securing access to affordable medicines.

DRAFT PROGRAMME

Monday, 8 October 2018	
8:30 – 9:00	Registration of Participants
9:00 – 9:15	Opening of the Workshop
9:15 – 9:45	Introduction of Participants
9:45 – 10:15	*Coffee Break*
Theme I: Setting the Scene	
10:15 – 11:30	Roundtable Discussion: Mapping the Interface between Health, Trade and Intellectual Property
11:30 – 12:15	Economics of Medical Technologies – Innovation and Access
12:15 – 12:30	Discussion
12:30 – 13:30	*Lunch Break*
Theme II: The Innovation Dimension	
13:30 – 15:00	The Intellectual Property System as Determinant for Innovation in the Pharmaceutical Sector: Implementing and Managing IPRs
15:00 – 15:15	Discussion
15:15 – 15:45	*Coffee Break*
15:45 – 16:45	Models for Collaboration: Public-Private Partnerships for Innovation and Access and Industry Partnerships
16:45 – 17:00	Discussion
17:00 – 18:00	*Breakout Session on Anti-Microbial Resistance: How to Foster Innovation, Access and Appropriate Use of Antibiotics*

Tuesday, 9 October 2018	
Theme III: The Access Dimension	
9:00 – 10:00	The Public Health Context and Overview of Determinants Related to Access
10:00 – 10:15	Discussion
10:15 – 10:45	*Coffee Break*
10:45 – 11:45	Using the IP System and its Policy Options to Further Global Access to Health
11:45 – 12:00	Discussion
12:00 – 12:30	The Doha Declaration on the TRIPS Agreement and Public Health and the TRIPS Amendment: Creating Legal Avenues for Access to Medicines
12:30 – 12:45	Discussion
12:45 – 13:45	*Lunch break*
13:45 – 14:15	Human Rights and Access to Medicines
14:15 – 14:30	Discussion
14:30 – 15:00	Selected Country Experiences – Presentations by Participants
15:00 – 15:30	*Coffee break*
15:30 – 16:30	Case Study – Pharmaceutical Industry Policy, Local Production of Medicines, Access, Strategies and Technology Transfer
Theme IV: Making Effective Use of Special Compulsory Licences for Export	
16:30 – 17:45	The Paragraph 6 System: • Background; • Practical Steps to Put the System to Work; and • Implementing Measures taken by WTO Members.
17:45 – 18:00	Discussion

Wednesday, 10 October 2018	
9:00 – 10:30	Case Study
10:30 – 11:00	*Coffee break*
11:00 – 11:30	Mapping Patents in Supply Countries
11:30 – 12:00	Using Medicines Price Data and Meeting Regulatory Requirements
12:00 – 12:20	Contributing to the Effective Working of the System as an Exporting Country
12:20 – 12:40	Implementing the System at the Regional Level
12:40– 13:00	Engaging in the Production of Generic Medicines under the System
13:00 – 14:00	*Lunch break*
14:00 – 14:30	Selected Country Experiences – Presentations by Participants
14:30 – 15:30	Panel Discussion: How to Enhance Synergies between Public Health Objectives and Trade Agreements: Industry and Civil Society Perspective
15:30 – 15:45	Discussion
15:45 – 16:15	*Coffee break*

Wednesday, 10 October 2018	
Theme V: The Trade Dimension	
16:15 – 17:15	Trends in Trade of Public Health Products and Other Trade-Related Access Determinants (Tariffs and Non-Tariff Measures)
17:15 – 17:30	Discussion

Thursday, 11 October 2018	
9:00 – 10:00	Trade in Health Services
10:00 – 10:15	Discussion
10:15 – 11:15	Procurement Rules and Practices
11:15 – 11:30	Discussion
11:30 – 12:30	*Lunch break*
12:30 – 13:30	Breakout Session on Non-Communicable Diseases: Multilateral initiatives and international programmes; trade and NCDs
13:30 – 14:15	Health-related Provisions in Regional Trade Agreements
14:15 – 14:30	Discussion
14:30 – 17:30	*Visit to a Medical Equipment Company*

Friday, 12 October 2018	
Theme IV: the Regulatory Dimension	
9:00 – 10:00	Competition Policy and Rules
10:00 – 11:00	Case Study
11:00 – 11:30	*Coffee break*
11:30 – 12:30	Approval, Quality Control and Effectiveness of Medicines, including Counterfeit, Falsified and Substandard Medicines
12:30 – 12:45	Discussion
12:45 – 13:45	*Lunch break*
13:45 – 14:30	Protection of Clinical Trial Data – Policy, Legal and Economic Aspects
14:30 – 14:45	Discussion
14:45 – 15:15	Standards, Health Regulation and Trade
15:15 – 15:30	Discussion
15:30 – 16:00	*Coffee break*
16:00 – 16:30	Health-Related Measures in the TBT and SPS Committees: Selected Specific Trade Concerns Raised by Members
16:30 – 17:30	Case Study
17:30 – 18:00	Closing remarks and Evaluation

_____